Hormonal
Orlistat reduces the incidence of type 2 diabetes in individuals with prediabetes or impaired glucose tolerance by approximately 37% over four years compared to placebo when combined with lifestyle changes.
If you are overweight and have prediabetes, adding orlistat (120mg with meals) to your lifestyle changes can significantly lower your risk of developing full-blown type 2 diabetes compared to lifestyle changes alone. Be mindful of your fat intake to minimize gastrointestinal side effects.
After 4 years of treatment, the cumulative risk of developing diabetes was 9.0% in the placebo group and 6.2% in the orlistat treatment group, corresponding to a risk reduction of 37.3%. Among 21% of the individuals with impaired glucose tolerance at baseline, the incidence of T2DM decreased by 45.0% over 4 years of orlistat therapy
Why this rating
Based on the XENDOS study, a 4-year RCT with 3,305 patients.
Source
Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
Rodrigo O. Moreira et al. · Archives of Endocrinology and Metabolism · 2024
DOI 10.20945/2359-4292-2024-0422
More from this paper
- Liraglutide 3.0 mg, a GLP-1 analogue, promotes weight loss and improves metabolic parameters through mechanisms involving hypothalamic energy balance regulation, glucose-dependent insulin stimulation, and slowed gastric emptying.Strong
- Sibutramine increases the risk of nonfatal cardiovascular events (myocardial infarction and stroke) in patients with pre-existing cardiovascular disease or type 2 diabetes with additional risk factors, leading to its contraindication in these populations.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →